Crosslinking Apigenin with Neurodevelopment: In-Vivo Model Designing based Therapeutic Strategy for Autism-Associated Neuroinflammation
DOI:
https://doi.org/10.36283/ziun-pjmd14-4/002Keywords:
Apigenin, Autism, Neuroinflammation, NGF, Neurodevelopment, In-Vivo ModelAbstract
Background: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder characterized by impaired social interaction, communication difficulties, and repetitive behaviors. Neuroinflammation is increasingly recognized as a key contributor to ASD pathophysiology. Nerve Growth Factor (NGF), a vital neurotrophin involved in neuronal survival and plasticity, is often dysregulated in ASD, exacerbating neurological dysfunction. Apigenin, a natural flavonoid with known anti-inflammatory and neuroprotective properties, has shown promise as a therapeutic agent in neurodevelopmental conditions. This study evaluated the effects of apigenin treatment on autism-like neuroinflammation by examining its impact on NGF regulation in a rodent model.
Methods: This in vivo study (July–November 2021) used 20 healthy male rats (8 weeks old). The research took place within the Animal House facility and was analyzed at SMDC Lahore and LUMHS Jamshoro, Sindh. Group I (n=4) was taken as control, while Groups II–V (n=16) received 250 mg/kg/day propionic acid (PPA) to induce autism-like neuroinflammation. Groups III–V were treated with Apigenin at 50, 100, and 200 mg/kg. NGF serum levels were analyzed using the enzyme-linked immunosorbent assay (ELISA). SPSS v 21 was used for statistical analysis using one-way ANOVA and Tukey’s test. p<0.05 was taken as significant.
Results: The levels of NGF were significantly lowered using propanoic acid (PPA) (4.3 ± 0.5 pg/mL vs control 11.9 ± 0.5). Apigenin dose-dependently restored NGF, with Group V (200 mg/kg) reaching 9.8 ± 0.5 pg/mL.
Conclusion: The neuroprotective properties of apigenin are evident through its ability to restore PPA-damaged levels of NGF, thus establishing potential use as an autism treatment for neuroinflammation in neurodevelopmental disorders.
References
1. Farooq MS, Tehseen R, Sabir M, Atal Z. Detection of autism spectrum disorder (ASD) in children and adults using machine learning. Sci Rep. 2023 Jun 13;13(1):9605. doi: 10.1038/s41598-023-35910-1.
2. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, et al. The global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-analysis. Ital J Pediatr. 2022 Jul 8;48(1):112. doi: 10.1186/s13052-022-01310-w.
3. Khachadourian V, Mahjani B, Sandin S, Kolevzon A, Buxbaum JD, Reichenberg A, et al. Comorbidities in autism spectrum disorder and their etiologies. Transl Psychiatry. 2023 Feb 25;13(1):71. doi: 10.1038/s41398-023-02374-w.
4. Usui N, Kobayashi H, Shimada S. Neuroinflammation and Oxidative Stress in the Pathogenesis of Autism Spectrum Disorder. Int J Mol Sci. 2023 Mar 13;24(6):5487. doi: 10.3390/ijms24065487.
5. Gevezova M, Sbirkov Y, Sarafian V, Plaimas K, Suratanee A, Maes M. Autistic spectrum disorder (ASD) - Gene, molecular and pathway signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling, and neurodevelopment. Brain Behav Immun Health. 2023 Jun 5;30:100646. doi: 10.1016/j.bbih.2023.100646.
6. Jayaprakash P, Isaev D, Yang KS, Beiram R, Oz M, Sadek B. Apigenin Alleviates Autistic-like Stereotyped Repetitive Behaviors and Mitigates Brain Oxidative Stress in Mice. Pharmaceuticals (Basel). 2024 Apr 9;17(4):482. doi: 10.3390/ph17040482.
7. Savino R, Medoro A, Ali S, Scapagnini G, Maes M, Davinelli S. The Emerging Role of Flavonoids in Autism Spectrum Disorder: A Systematic Review. J Clin Med. 2023 May 17;12(10):3520. doi: 10.3390/jcm12103520.
8. Anashkina AA, Erlykina EI. Molecular Mechanisms of Aberrant Neuroplasticity in Autism Spectrum Disorders (Review). Sovrem Tekhnologii Med. 2021;13(1):78-91. doi: 10.17691/stm2021.13.1.10.
9. Gevezova M, Minchev D, Pacheva I, Todorova T, Yordanova R, Timova E, et al. Association of NGF and Mitochondrial Respiration with Autism Spectrum Disorder. Int J Mol Sci. 2022 Oct 7;23(19):11917. doi: 10.3390/ijms231911917.
10. Jian J, Li LG, Zhao PJ, Zheng RJ, Dong XW, Zhao YH, et al. Mouse nerve growth factor suppresses neuronal apoptosis in valproic acid-induced autism spectrum disorder rats by regulating the phosphoinositide-3-kinase/serine/threonine kinase signaling pathway. Pharmacogenet Genomics. 2023 Jul 1;33(5):101-110. doi: 10.1097/FPC.0000000000000498.
11. Lagod PP, Abdelli LS, Naser SA. An In Vivo Model of Propionic Acid-Rich Diet-Induced Gliosis and Neuro-Inflammation in Mice (FVB/N-Tg(GFAPGFP)14Mes/J): A Potential Link to Autism Spectrum Disorder. Int J Mol Sci. 2024 Jul 25;25(15):8093. doi: 10.3390/ijms25158093.
12. Erdogan MA, Akbulut MC, Altuntaş İ, Tomruk C, Uyanıkgil Y, Erbaş O. Amelioration of propionic acid-induced autism-like behaviors in rats by fenofibrate: A focus on reduction of brain galectin-3 levels. Int J Dev Neurosci. 2024 Dec;84(8):977-990. doi: 10.1002/jdn.10393.
13. Kumar V, Kundu S. Studies on Apigenin and Its Biological and Pharmacological Activity in Brain Disorders. Adv Pharm Bull. 2022 Aug;12(4):645-648. doi: 10.34172/apb.2022.068.
14. Wasim M, Zia SR, Ahmad S. Molecular Docking Analysis Reveals the Promising Role of Apigenin as a Potential Treatment for Neurological Disorders. Clin Neuropharmacol. 2024 Sep-Oct 01;47(5):176-180. doi: 10.1097/WNF.0000000000000608.
15. Olasehinde TA, Olaokun OO. Apigenin and inflammation in the brain: can apigenin inhibit neuroinflammation in preclinical models? Inflammopharmacology. 2024 Oct;32(5):3099-3108. doi: 10.1007/s10787-024-01538-4.
16. Farbin M, Hejazi A, Fakhraei N, Azizi Y, Mehrabi S, Hajisoltani R. Neuroprotective effects of Apigenin on prenatal Valproic acid-induced autism spectrum disorder in rats. IBRO Neurosci Rep. 2024 Oct 30;17:493-502. doi: 10.1016/j.ibneur.2024.10.003.
17. Singh AA, Katiyar S, Song M. Phytochemicals Targeting BDNF Signaling for Treating Neurological Disorders. Brain Sci. 2025 Feb 27;15(3):252. doi: 10.3390/brainsci15030252.
18. Wang L, Wang B, Wu C, Wang J, Sun M. Autism Spectrum Disorder: Neurodevelopmental Risk Factors, Biological Mechanism, and Precision Therapy. Int J Mol Sci. 2023 Jan 17;24(3):1819. doi: 10.3390/ijms24031819.
19. Arda DB, Tunç KC, Bozkurt MF, Bora ES, Çiğel A, Erbaş O. Intranasal Insulin Eases Autism in Rats via GDF-15 and Anti-Inflammatory Pathways. Curr Issues Mol Biol. 2024 Sep 20;46(9):10530-10544. doi: 10.3390/cimb46090624.
20. Cruz-Martins N, Quispe C, Kırkın C, Şenol E, Zuluğ A, Özçelik B, et al. Paving Plant-Food-Derived Bioactives as Effective Therapeutic Agents in Autism Spectrum Disorder. Oxid Med Cell Longev. 2021 Aug 21;2021:1131280. doi: 10.1155/2021/1131280.
21. Grosso C, Santos M, Barroso MF. From Plants to Psycho-Neurology: Unravelling the Therapeutic Benefits of Bioactive Compounds in Brain Disorders. Antioxidants (Basel). 2023 Aug 11;12(8):1603. doi: 10.3390/antiox12081603.
22. Mohammedsaeed W, Alharbi M. Biochemical Markers as Predictors of Health Outcomes in Autism Spectrum Disorder: A Comprehensive Systematic Review and Meta-analysis. J Mol Neurosci. 2025 Feb 6;75(1):17. doi: 10.1007/s12031-024-02306-3.
23. Noori AS, Rajabi P, Sargolzaei J, Alaghmand A. Correlation of biochemical markers and inflammatory cytokines in autism spectrum disorder (ASD). BMC Pediatr. 2024 Nov 1;24(1):696. doi: 10.1186/s12887-024-05182-3.
24. Kuru Bektaşoğlu P, Demir D, Koyuncuoğlu T, Yüksel M, Peker Eyüboğlu İ, Karagöz Köroğlu A, et al. Possible anti-inflammatory, antioxidant, and neuroprotective effects of apigenin in the setting of mild traumatic brain injury: an investigation. Immunopharmacol Immunotoxicol. 2023 Apr;45(2):185-196. doi: 10.1080/08923973.2022.2130076.
25. Faysal M, Dehbia Z, Zehravi M, Sweilam SH, Haque MA, Kumar KP, et al. Flavonoids as Potential Therapeutics Against Neurodegenerative Disorders: Unlocking the Prospects. Neurochem Res. 2024 Aug;49(8):1926-1944. doi: 10.1007/s11064-024-04177-x.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
